COVID-19 infection-associated multisystem inflammatory syndrome and cytokine storms in children

doi:10.11958/20220587

Abstract

Abstract:

Multisystem inflammatory syndrome in children (MIS-C) is a systemic inflammatory syndrome with multi-organ dysfunctions. Most of the children have evidence of severe acute respiratory syndrome-associated coronavirus (SARS-CoV-2) infection or a history of exposure to patients with coronavirus disease 2019 (COVID-19). Children often present with fever, gastrointestinal symptoms, cardiac dysfunctions, shock and other multi-system symptoms. Cytokine storm (CS) is an inflammatory response triggered by external stimulations. Factors causing CS include iatrogenic, pathogenic, monogenic or autoimmune diseases. The pathogenesis of MIS-C is still unclear, which may be related to the over-response of immune system caused by SARS-CoV-2 infections. In this paper, the clinical characteristics of COVID-19 infection-related MIS-C are summarized, and the relationship between MIS-C and CS is discussed, aiming to provide references for the mechanistic investigation and clinical diagnosis of MIS-C.

Key words: coronavirus infections, child, COVID-19, multisystem inflammatory syndrome in children, cytokine storm

CLC Number:

R725.1

References 51

[1]	CASTAGNOLI R, VOTTO M, LICARI A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents:A systematic review[J]. JAMA Pediatr, 2020, 174(9):882-889. doi:10.1001/jamapediatrics.2020.1467.
[2]	DONG Y, MO X, HU Y, et al. Epidemiology of COVID-19 among children in China[J]. Pediatrics, 2020, 145(6):e20200702. doi:10.1542/peds.2020-0702.
[3]	NAKRA N A, BLUMBERG D A, HERRERA-GUERRA A, et al. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection:Review of clinical presentation,hypothetical pathogenesis,and proposed management[J]. Children(Basel), 2020, 7(7):69. doi:10.3390/children7070069.
[4]	FUNK A L, FLORIN T A, KUPPERMANN N, et al. Outcomes of SARS-CoV-2-positive youths tested in emergency departments:The Global PERN-COVID-19 Study[J]. JAMA Netw Open, 2022, 5(1):e2142322. doi:10.1001/jamanetworkopen.2021.42322.
[5]	WHITTAKER E, BAMFORD A, KENNY J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2[J]. JAMA, 2020, 324(3):259-269. doi:10.1001/jama.2020.10369.
[6]	BELHADJER Z, MÉOT M, BAJOLLE F, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic[J]. Circulation, 2020, 142(5):429-436. doi:10.1161/CIRCULATIONAHA.120.048360.
[7]	TOUBIANA J, POIRAULT C, CORSIA A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris,France:prospective observational study[J]. BMJ, 2020, 369: m2094. doi:10.1136/bmj.m2094.
[8]	KWAK J H, LEE S Y, CHOI J W. Clinical features,diagnosis,and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019[J]. Clin Exp Pediatr, 2021, 64(2):68-75. doi:10.3345/cep.2020.01900.
[9]	YANG X, YU Y, XU J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,China:a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8(5):475-481. doi:10.1016/s2213-2600(20)30079-5.
[10]	ROTHAN H A, BYRAREDDY S N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak[J]. J Autoimmun, 2020, 109:102433. doi:10.1016/j.jaut.2020.102433.
[11]	TISONCIK J R, KORTH M J, SIMMONS C P, et al. Into the eye of the cytokine storm[J]. Microbiol Mol Biol Rev, 2012, 76(1):16-32. doi:10.1128/MMBR.05015-11.
[12]	YANG M C, TSAI C C, SU Y T, et al. The emergence of a new cytokine storm during the COVID-19 pandemic:Multisystem inflammatory syndrome in children[J]. Kaohsiung J Med Sci, 2021, 37(3):255-256. doi:10.1002/kjm2.12347.
[13]	KAUSHIK A, GUPTA S, SOOD M, et al. A systematic review of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection[J]. Pediatr Infect Dis J, 2020, 39(11):e340-e346. doi:10.1097/INF.0000000000002888.
[14]	RADIA T, WILLIAMS N, AGRAWAL P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C):A systematic review of clinical features and presentation[J]. Paediatr Respir Rev, 2021, 38:51-57. doi:10.1016/j.prrv.2020.08.001.
[15]	JIANG L, TANG K, LEVIN M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents[J]. Lancet Infect Dis, 2020, 20(11):e276 -e288. doi:10.1016/s1473-3099(20)30651-4.
[16]	MAGBOUL S, KHALIL A, HASSAN M, et al. Multisystem inflammatory syndrome in children(MIS-C)related to COVID-19 infection in the state of Qatar:Association with Kawasaki-like Illness[J]. Acta Biomed, 2022, 92(6):e2021543. doi:10.23750/abm.v92i6.11991.
[17]	MOREEWS M, LE GOUGE K, KHALDI-PLASSART S, et al. Polyclonal expansion of TCR Vbeta 21.3(+) CD4(+) and CD8(+) T cells is a hallmark of multisystem inflammatory syndrome in Children[J]. Sci Immunol, 2021, 6(59):eabh1516. doi:10.1126/sciimmunol.abh1516.
[18]	PIERCE C A, PRESTON-HURLBURT P, DAI Y, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients[J]. Sci Transl Med, 2020, 12(564):eabd5487. doi:10.1126/scitranslmed.abd5487.
[19]	CARTER M J, SHANKAR-HARI M, TIBBY S M. Paediatric inflammatory multisystem syndrome temporally-associated with SARS-CoV-2 infection:An overview[J]. Intensive Care Med, 2021, 47(1):90-93. doi:10.1007/s00134-020-06273-2.
[20]	AHMED M, ADVANI S, MOREIRA A, et al. Multisystem inflammatory syndrome in children:A systematic review[J]. EClinicalMedicine, 2020, 26:100527. doi:10.1016/j.eclinm.2020.100527.
[21]	PAWAR R S, AKHELIKAR N S, KURANE A B. Acute severe heart failure in a child with congenital heart defect and multisystem inflammatory syndrome in children (MIS-C)[J]. Indian Pediatr, 2021, 58(10):996-997. doi:10.1007/s13312-021-2341-0.
[22]	FELDSTEIN L R, ROSE E B, HORWITZ S M, et al. Multisystem inflammatory syndrome in U.S. children and adolescents[J]. N Engl J Med, 2020, 383(4):334-346. doi:10.1056/NEJMoa2021680.
[23]	SHARMA C, GANIGARA M, GALEOTTI C, et al. Multisystem inflammatory syndrome in children and Kawasaki disease:A critical comparison[J]. Nat Rev Rheumatol, 2021, 17(12):731-748. doi:10.1038/s41584-021-00709-9.
[24]	LIN M T, WU M H. The global epidemiology of Kawasaki disease:Review and future perspectives[J]. Glob Cardiol Sci Pract, 2017, 2017(3): e201720. doi:10.21542/gcsp.2017.20.
[25]	张莉, 雷亚茹, 石瑜, 等. 儿童多系统炎症综合征研究进展[J]. 传染病信息, 2021, 34(4):291-295.
	ZHANG L, LEI Y R, SHI Y, et al. Research progress in multisystem inflammatory syndrome in children[J]. Infect Dis Info, 2021, 34(4):291-295. doi:10.3969/j.issn.1007-8134.2021.04.002.
[26]	RAFFERTY M S, BURROWS H, JOSEPH J P, et al. Multisystem inflammatory syndrome in children (MIS-C) and the coronavirus pandemic:Current knowledge and implications for public health[J]. J Infect Public Health, 2021, 14(4):484-494. doi:10.1016/j.jiph.2021.01.008.
[27]	ZUO Y, YALAVARTHI S, SHI H, et al. Neutrophil extracellular traps in COVID-19[J]. JCI Insight, 2020, 5(11):e138999. doi:10.1172/jci.insight.138999.
[28]	MIDDLETON E A, HE X Y, DENORME F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome[J]. Blood, 2020, 136(10):1169-1179. doi:10.1182/blood.2020007008.
[29]	BLONDIAUX E, PARISOT P, REDHEUIL A, et al. Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19[J]. Radiology, 2020, 297(3):E283-E288. doi:10.1148/radiol.2020202288.
[30]	GAITONDE M, ZIEBELL D, KELLEMAN M S, et al. COVID-19-related multisystem inflammatory syndrome in children affects left ventricular function and global strain compared with Kawasaki disease[J]. J Am Soc Echocardiogr, 2020, 33(10):1285-1287. doi:10.1016/j.echo.2020.07.019.
[31]	DIORIO C, HENRICKSON S E, VELLA L A, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2[J]. J Clin Invest, 2020, 130(11):5967-5975. doi:10.1172/JCI140970.
[32]	ABRAMS J Y, OSTER M E, GODFRED-CATO S E, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA:a retrospective surveillance study[J]. Lancet Child Adolesc Health, 2021, 5(5):323-331. doi:10.1016/s2352-4642(21)00050-x.
[33]	OULDALI N, YANG D D, MADHI F, et al. Factors associated with severe SARS-CoV-2 infection[J]. Pediatrics, 2021, 147(3):e2020023432. doi:10.1542/peds.2020-023432.
[34]	YE Q, WANG B, MAO J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19[J]. J Infect, 2020, 80(6):607-613. doi:10.1016/j.jinf.2020.03.037.
[35]	DOLINGER M T, PERSON H, SMITH R, et al. Pediatric Crohn disease and multisystem inflammatory syndrome in children (MIS-C) and COVID-19 treated with infliximab[J]. J Pediatr Gastroenterol Nutr, 2020, 71(2):153-155. doi:10.1097/MPG.0000000000002809.
[36]	FAJGENBAUM D C, JUNE C H. Cytokine Storm[J]. N Engl J Med, 2020, 383(23):2255-2273. doi:10.1056/NEJMra2026131.
[37]	GRUPP S A, KALOS M, BARRETT D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med, 2013, 368(16):1509-1518. doi:10.1056/NEJMoa1215134.
[38]	王玉亮, 王峰, 耿洁. 细胞因子与细胞因子风暴[J]. 天津医药, 2020, 48(6):494-499.
	WANG Y L, WAN F, GENG J. Cytokine and cytokine storm[J]. Tianjin Med J, 2020, 48(6):494-499. doi:10.11958/20200323.
[39]	刘爱良, 鲍燕敏, 郑跃杰, 等. 呼吸道病毒感染相关细胞因子风暴与靶向治疗策略[J]. 中华实用儿科临床杂志, 2021, 36(24):1913-1917.
	LIU A L, BAO Y M, ZHENG Y J, et al. Cytokine storms associated with respiratory virus infection and targeted therapy strategies[J]. Chin J Appl Clin Pediatr, 2021, 36(24):1913-1917. doi:10.3760/cma.j.cn101070-20210809-00943.
[40]	KARKI R, KANNEGANTI T D. The 'cytokine storm':molecular mechanisms and therapeutic prospects[J]. Trends Immunol, 2021, 42(8):681-705. doi:10.1016/j.it.2021.06.001.
[41]	GODFRED-CATO S, BRYANT B, LEUNG J, et al. COVID-19-associated multisystem inflammatory syndrome in children-United States,March-July 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(32):1074-1080. doi:10.15585/mmwr.mm6932e2.
[42]	PARK A, IWASAKI A. Type Ⅰ and type Ⅲ interferons-induction, signaling,evasion,and application to combat COVID-19[J]. Cell Host Microbe, 2020, 27(6):870-878. doi:10.1016/j.chom.2020.05.008.
[43]	安纪红. 感染与细胞因子风暴[J]. 中华实验和临床感染病杂志(电子版), 2013, 7(6):925-926.
	AN J H. Infection and cytokine storms[J]. Chin J Exp Clin Infect Dis (Electronic Edition),2013, 7(6):925-926. doi:10.3877/cma.j.issn.1674-1358.2013.06.035.
[44]	CHEN G, WU D, GUO W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019[J]. J Clin Invest, 2020, 130(5):2620-2629. doi:10.1172/JCI137244.
[45]	冯志冠, 鲍燕敏, 杨永弘, 等. 新型冠状病毒感染相关儿童多系统炎症综合征[J]. 中华实用儿科临床杂志, 2020, 35(15):1121-1124.
	FENG Z G, BAO Y M, YANG Y H, et al. Multisystem inflammatory syndrome in children related with 2019 Novel Coronavirus infection[J]. Chin J Appl Clin Pediatr, 2020, 35(15):1121-1124. doi:10.3760/cma.j.cn101070-20200710-01156.
[46]	HU K, GUAN W J, BI Y, et al. Efficacy and safety of Lianhuaqingwen capsules,a repurposed Chinese herb,in patients with coronavirus disease 2019:A multicenter,prospective,randomized controlled trial[J]. Phytomedicine, 2021, 85:153242. doi:10.1016/j.phymed.2020.153242.
[47]	CHEN Y, LIU C, WANG T, et al. Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection:A multicentre,double-blind, and randomised controlled trial[J]. J Ethnopharmacol, 2022, 284:114830. doi:10.1016/j.jep.2021.114830.
[48]	ZHANG L, ZHENG X, BAI X, et al. Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19:A national retrospective registry study[J]. Phytomedicine, 2021, 85:153531. doi:10.1016/j.phymed.2021.153531.
[49]	CHEN X, FENG Y, SHEN X, et al. Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro- and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis[J]. J Ethnopharmacol, 2018, 211:358-365. doi:10.1016/j.jep.2017.10.001.
[50]	YANG R, LIU H, BAI C, et al. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19):In silico and experimental study[J]. Pharmacol Res, 2020, 157:104820. doi:10.1016/j.phrs.2020.104820.
[51]	池里群, 周彬, 高文远, 等. 治疗类风湿性关节炎常用药物的研究进展[J]. 中国中药杂志, 2014, 39(15):2851-2858.
	CHI L Q, ZHOU B, GAO W Y, et al. Research progress of drugs commonly used to anti-rheumatoid arthritis[J]. China Journal of Chinese Materia Medica, 2014, 39(15):2851-2858. doi:10.4268/cjcmm20141512.